Platelet News and Research

RSS

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium.

21 Sep 2013

Oil spill exposure appears to play role in development of hematologic and hepatic toxicity

A new study reports that workers exposed to crude oil and dispersants used during the Gulf oil spill cleanup display significantly altered blood profiles, liver enzymes, and somatic symptoms compared to an unexposed control group.

17 Sep 2013

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

A shortened pre-surgical interruption of anti-thrombotic therapy, compared to the more traditional one-week interruption, has no influence on perioperative complications in cardiac patients, according to the results of the PRAGUE 14 trial.

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Golgi apparatus: New target for treatment of acute cerebral infarction

Expression of soluble CD40L has been shown to increase sig-nificantly in conditions such as stroke, myocardial infarction, unstable angina, high cholesterol, or other cardiovascular events. 95% of the circulating CD40L exists in activated platelets.

5 Sep 2013

Secondary prevention drugs produce decline in stroke risk after AMI in diabetic patients

The findings were presented at the ESC Congress today by Ms Stina Jakobsson from Sweden. They reveal that reperfusion therapy and secondary prevention drugs produced the decline and brought stroke risk after AMI closer to that of non-diabetics.

5 Sep 2013

Study: Fixed-dose combination medication helps CVD patients

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA.

4 Sep 2013

Increased risk caused by smoking is completely reversed after smoking cessation

Dr Dohi said: "Smokers are twice as likely to have a heart attack as people who have never smoked. Quitting smoking is the most important thing people can do to reduce their risk of cardiovascular disease. But until now, studies have not examined whether the increased risk caused by smoking is completely reversed after smoking cessation."

4 Sep 2013

Findings challenge existing paradigms for prolonging antiplatelet therapy after PCI

Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European Society of Cardiology.

3 Sep 2013

Low temperature triggers acute myocardial infarction

Professor Claeys said: "Air pollution and temperature changes are the most frequently reported environmental triggers for acute myocardial infarction (AMI). Epidemiologic studies have focused mainly on one environmental condition, but most environmental triggers are related to each other and may attenuate or reinforce the triggering effect of a single environmental factor."

2 Sep 2013

New angle for developing drugs to prevent thrombosis and heart attack

Platelets, which allow blood to clot, are at the heart of numerous cardiovascular problems, including heart attacks and stroke. New research has uncovered a key platelet protein that could offer a new angle for developing drugs to prevent thrombosis, or dangerous blood clots, in patients who are at high risk such as those with atherosclerosis or a history of heart problems.

31 Aug 2013

Research suggests clingy blood platelets may offer hope for people with rheumatoid arthritis

No one likes clingy people, but "clingy" blood platelets may offer hope for millions of people with rheumatoid arthritis. According to new research findings published in The Journal of Leukocyte Biology, a sub population of immune cells (lymphocytes) known to play a significant role in rheumatoid arthritis has platelets attached to their surface.

30 Aug 2013

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt has added genetic screening for the drug tacrolimus to its personalize medicine pharmacogenomics program PREDICT. The new drug screening protocol was added following data that shows a single genetic variation largely impacts different dose requirements for patients.

27 Aug 2013

Risk factors linked to death may be reversible in severe encephalitis patients

People with severe encephalitis - inflammation of the brain - are much more likely to die if they develop severe swelling in the brain, intractable seizures or low blood platelet counts, regardless of the cause of their illness, according to new Johns Hopkins research.

21 Aug 2013

Immunetics receives FDA clearance for BacTx rapid test for bacteria in apheresis platelets

mmunetics, Inc., a leading clinical test provider, has received U.S. Food and Drug Administration (FDA) clearance for its BacTx® rapid test for bacteria in apheresis platelets. The BacTx system is a colorimetric assay that can detect aerobic, anaerobic, gram-negative and gram-positive bacteria in a single test.

20 Aug 2013

Older heart patients present unique challenges for determining optimal dosages of medications

Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks.

17 Aug 2013

Neurologist writes "explosion of new and innovative" therapies for neurologic conditions

There has been an "explosion of new and innovative" therapies for neurologic conditions such as stroke, epilepsy, Parkinson disease and multiple sclerosis, Loyola University Medical Center neurologist Dr. Jose Biller writes in the August issue of the journal Neurologic Clinics.

16 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

ASH to award 2013 William Dameshek Prize to Andrew S. Weyrich

The American Society of Hematology will present the 2013 William Dameshek Prize to Andrew S. Weyrich, PhD, of The University of Utah for his seminal research on the cellular and molecular causes of blood clots.

2 Aug 2013

Platelet News and Research

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

Oil spill exposure appears to play role in development of hematologic and hepatic toxicity

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Golgi apparatus: New target for treatment of acute cerebral infarction

Secondary prevention drugs produce decline in stroke risk after AMI in diabetic patients

Study: Fixed-dose combination medication helps CVD patients

Increased risk caused by smoking is completely reversed after smoking cessation

Findings challenge existing paradigms for prolonging antiplatelet therapy after PCI

Low temperature triggers acute myocardial infarction

New angle for developing drugs to prevent thrombosis and heart attack

Research suggests clingy blood platelets may offer hope for people with rheumatoid arthritis

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Risk factors linked to death may be reversible in severe encephalitis patients

Immunetics receives FDA clearance for BacTx rapid test for bacteria in apheresis platelets

Older heart patients present unique challenges for determining optimal dosages of medications

Neurologist writes "explosion of new and innovative" therapies for neurologic conditions

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

ASH to award 2013 William Dameshek Prize to Andrew S. Weyrich

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News